Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the ...

Drugmakers Baxter International and Claris Injectables ... of Claris' rights to fluconazole in saline intravenous bags and milrinone in dextrose intravenous bags to New Jersey-based pharmaceutical ...

A head-to-head comparison of inotropes in the setting of cardiogenic shock revealed no clear victor, with milrinone and dobutamine providing similar outcomes in the randomized DOREMI trial. A ...

A head-to-head randomized comparison of milrinone and dobutamine — the most used inotropes in cardiogenic shock therapy in North America — failed to find a significant advantage for one agent ...

The researchers found that the primary outcome was similar between the two groups (49 percent in the milrinone group and 54 percent in the dobutamine group; relative risk [RR], 0.90; 95 percent ...

Please provide your email address to receive an email when new articles are posted on . Among patients with cardiogenic shock, there was no difference between the inotropic agents milrinone and ...

Bedford Laboratories announced the addition of milrinone lactate in 5% dextrose injection (0.2mg/mL) in single-dose PVC flexible containers to its existing milrinone injection line. This product ...

Patients with cardiogenic shock were assigned to receive milrinone or dobutamine for inotropic support. There was no significant difference between the two groups in the composite primary outcome ...